Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Foundation Medicine's FoundationOne blood test wins FDA companion diagnostic approval for Pfizer's Talzenna (talazoparib) in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer
Small molecule, cancer, PARP inhibitor, prostate cancer, companion diagnostic, HRR gene mutation - Read more

Lupin, Natco Pharma receive FDA approval for generic eribulin mesylate injection for metastatic breast cancer and liposarcoma
Small molecule, cancer, chemotherapy, breast cancer, liposarcoma, generic drug - Read more

Regeneron expands CytomX Therapeutics pact on conditionally active bispecifics, $37M upfront, ~$4B total value
Research collaboration, oncology, bispecific antibody, milestone payments, drug discovery - Read more

Eli Lilly, Ascidian Therapeutics partner on RNA exon editing for kidney diseases, up to $1.9B
Licensing deal, kidney disease, RNA editing, milestone payments, royalties - Read more

Causaly, Microsoft collaborate to integrate scientific computation with knowledge-graph reasoning for life sciences R&D
Research collaboration, AI/ML, drug discovery, R&D, knowledge graph - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Legend Biotech's (LB2501) achieves 100% response rate in Ph1 non-Hodgkin lymphoma in vivo CAR T study
Cell therapy, cancer, CAR-T, in vivo CAR-T, non-Hodgkin lymphoma, B cell lymphoma - Read more

JJP Biologics reports positive Ph1b interim data for (nebaprubart) targeting CD89 in linear IgA disease
Antibody, autoimmune, monoclonal antibody, linear IgA disease, CD89 target, IgA-mediated disease - Read more

GSK's velzatinib (IDRX-42) shows 61% response rate in Ph1/Ib for first-line gastrointestinal stromal tumour
Small molecule, cancer, tyrosine kinase inhibitor, gastrointestinal stromal tumor, KIT mutation, imatinib resistance - Read more

Johnson & Johnson's nipocalimab meets primary endpoint in Ph2 study for moderate-to-severe systemic lupus erythematosus
Antibody, autoimmune, monoclonal antibody, systemic lupus erythematosus, FcRn blockade, IgG autoantibodies - Read more

Zenas BioPharma releases Ph3 data for (obexelimab) targeting CD19/FcγRIIb in immunoglobulin G4-related disease
Antibody, autoimmune, monoclonal antibody, IgG4-related disease, CD19, FcγRIIb - Read more

OS Therapies' OST-HER2 Ph2b trial achieves 75% 2.5-year survival in metastatic osteosarcoma
Antibody, cancer, monoclonal antibody, osteosarcoma, HER2, immunotherapy - Read more

IMU Biosciences raises $53M Series A to decode immune system, expand clinical platform
Immunology, AI/ML platform, multi-omics, biomarker discovery, clinical-stage - Read more

NewLimit raises $435M Series C, advancing epigenetic reprogramming medicine toward human trials
Aging biology, epigenetic reprogramming, AI/ML platform, liver disease, preclinical - Read more

Ingenix raises €13M ($15.1M) seed-extension, scaling AI Modality Fusion architecture for drug development
AI/ML platform, drug discovery, platform technology, biology reasoning, multi-modal - Read more

Tavo Biotherapeutics raises $17M Series A to advance glaucoma and retinal disease therapies
Ophthalmology, glaucoma, retinal disease, clinical-stage - Read more

Ilant Health raises $15M Series A, AI-supported precision obesity care for employers and health plans
Obesity care, AI-driven, value-based care, precision care, digital health - Read more

Genomics expands Mystra platform with agentic AI to accelerate drug target discovery and validation
Agentic AI, drug discovery, operational, competitive - Read more

Novo Nordisk launches Wegovy pill in UAE, marking first international rollout of oral obesity treatment
Small molecule, obesity, cardiovascular, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Eli Lilly threatens to cut 340B hospital discounts over data-sharing non-compliance by Monday deadline
340B drug pricing, small molecule, operational, regulatory, financial - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here